La Jolla Pharmaceutical Co (LJPC)

17.23
0.13 0.76
NASDAQ : Health Care
Prev Close 17.10
Open 17.06
Day Low/High 17.00 / 17.74
52 Wk Low/High 12.68 / 44.99
Volume 41.86K
Avg Volume 125.90K
Exchange NASDAQ
Shares Outstanding 18.25M
Market Cap 320.91M
EPS -2.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

La Jolla Pharmaceutical Company To Provide Corporate Overview At The Jefferies 2016 Global Healthcare Conference

La Jolla Pharmaceutical Company To Provide Corporate Overview At The Jefferies 2016 Global Healthcare Conference

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

5 Stocks Triggering Breakout Trades

5 Stocks Triggering Breakout Trades

These stocks are setting up to break out and trade higher from current levels.

Jim Cramer's 'Mad Money' Recap: These 5 Are Falling for Holding Too Much Cash

Jim Cramer's 'Mad Money' Recap: These 5 Are Falling for Holding Too Much Cash

Apple, Microsoft and three others are not being rewarded for their success and frugality, Cramer says.

Relative Strength Alert For La Jolla Pharmaceutical

Relative Strength Alert For La Jolla Pharmaceutical

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results And Recent Corporate Progress

La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results And Recent Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases,...

Commit To Buy La Jolla Pharmaceutical At $17.50, Earn 28% Annualized Using Options

Commit To Buy La Jolla Pharmaceutical At $17.50, Earn 28% Annualized Using Options

Investors eyeing a purchase of La Jolla Pharmaceutical Co. stock, but cautious about paying the going market price of $22.34/share, might benefit from considering selling puts among the alternative strategies at their disposal.

La Jolla Pharmaceutical Company To Provide Corporate Overview At The Cowen And Company 36th Annual Health Care Conference

La Jolla Pharmaceutical Company To Provide Corporate Overview At The Cowen And Company 36th Annual Health Care Conference

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Company Announces Fourth Quarter And Full Year 2015 Financial Results And Highlights Corporate Progress

La Jolla Pharmaceutical Company Announces Fourth Quarter And Full Year 2015 Financial Results And Highlights Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Becomes Oversold (LJPC)

La Jolla Pharmaceutical Becomes Oversold (LJPC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

La Jolla Pharmaceutical Company To Provide Corporate Overview At The 2016 BIO CEO & Investor Conference

La Jolla Pharmaceutical Company To Provide Corporate Overview At The 2016 BIO CEO & Investor Conference

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

Short Interest Jumps 24% For LJPC

Short Interest Jumps 24% For LJPC

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 317,740 share increase in total short interest for La Jolla Pharmaceutical Co. , to 1,640,851, an increase of 24.01% since 12/15/2015.

La Jolla Pharmaceutical Enters Oversold Territory (LJPC)

La Jolla Pharmaceutical Enters Oversold Territory (LJPC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Purchase La Jolla Pharmaceutical At $17.50, Earn 25.9% Annualized Using Options

Commit To Purchase La Jolla Pharmaceutical At $17.50, Earn 25.9% Annualized Using Options

Investors considering a purchase of La Jolla Pharmaceutical Co. stock, but tentative about paying the going market price of $25.94/share, might benefit from considering selling puts among the alternative strategies at their disposal.

La Jolla Pharmaceutical Company Announces Notice Of Allowance For U.S. Patent Covering LJPC-501

La Jolla Pharmaceutical Company Announces Notice Of Allowance For U.S. Patent Covering LJPC-501

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical (LJPC) Weak On High Volume Today

La Jolla Pharmaceutical (LJPC) Weak On High Volume Today

Trade-Ideas LLC identified La Jolla Pharmaceutical (LJPC) as a weak on high relative volume candidate

La Jolla Pharmaceutical Company Announces Third Quarter 2015 Financial Results And Recent Corporate Progress

La Jolla Pharmaceutical Company Announces Third Quarter 2015 Financial Results And Recent Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Company Doses First Patient In Phase 1 Clinical Trial Of LJPC-401 In Patients At Risk Of Iron Overload

La Jolla Pharmaceutical Company Doses First Patient In Phase 1 Clinical Trial Of LJPC-401 In Patients At Risk Of Iron Overload

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

'Mad Money' Lightning Round: Take PPG Over Sherwin-Williams

'Mad Money' Lightning Round: Take PPG Over Sherwin-Williams

Cramer says to wait on Johnson Controls and avoid Jacobs Engineering.

Jim Cramer's 'Mad Money' Recap: 5 Groups You Once Loved but Now Hate

Jim Cramer's 'Mad Money' Recap: 5 Groups You Once Loved but Now Hate

Cramer says these five groups must be approached with caution.

First Week of November 20th Options Trading For La Jolla Pharmaceutical (LJPC)

First Week of November 20th Options Trading For La Jolla Pharmaceutical (LJPC)

Investors in La Jolla Pharmaceutical Co. saw new options become available this week, for the November 20th expiration.

La Jolla Pharmaceutical Company Closes Offering Of Common Stock

La Jolla Pharmaceutical Company Closes Offering Of Common Stock

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Company Receives Positive Opinion From European Orphan Committee For LJPC-401

La Jolla Pharmaceutical Company Receives Positive Opinion From European Orphan Committee For LJPC-401

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Company Announces Pricing Of Underwritten Offering Of Common Stock

La Jolla Pharmaceutical Company Announces Pricing Of Underwritten Offering Of Common Stock

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering Of Common Stock

La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering Of Common Stock

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Company Receives Orphan Drug Designation For Two Novel Compounds For Fibrodysplasia Ossificans Progressiva

La Jolla Pharmaceutical Company Receives Orphan Drug Designation For Two Novel Compounds For Fibrodysplasia Ossificans Progressiva

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Company And Vanderbilt University Enter Exclusive Research And License Agreement Covering Novel BMP Type-I Receptor Inhibitors

La Jolla Pharmaceutical Company And Vanderbilt University Enter Exclusive Research And License Agreement Covering Novel BMP Type-I Receptor Inhibitors

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Company Announces FDA Acceptance Of IND For LJPC-401

La Jolla Pharmaceutical Company Announces FDA Acceptance Of IND For LJPC-401

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Company Announces Second Quarter 2015 Financial Results And Recent Corporate Progress

La Jolla Pharmaceutical Company Announces Second Quarter 2015 Financial Results And Recent Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...